



IMUGENE

Developing Cancer Immunotherapies

ASX: IMU

DEVELOPING TRANSFORMATIVE CANCER MEDICINES

Annual General Meeting 2023
CEO Presentation



ersonal use only

DISCLAIMER

1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Imugene Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.
2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.
3. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.
4. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.
5. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change
6. International offer restrictions - This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. In particular, the New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.


INTERNATIONAL LEADERSHIP TEAM WITH EXTENSIVE COMMERCIALISATION EXPERTISE IN THE SECTOR

Imugene has a team with vast oncology drug development experience



IMUGENE CLINICAL EXECUTIVE TEAM

Over 150 years of combined experience in Clinical Development
13 FDA Approved Drugs to market



INVESTMENT HIGHLIGHTS

MARKET CAPITALISATION

29 November 2023

A\$752M
US\$496M



CASH AS OF

30 September 2023

A\$163M
US\$104M



3

PRIORITY PLATFORM TECHNOLOGIES

Allo CAR T Cell Therapy

onCARlytics


CF33 Oncolytic Virus

IN-HOUSE GMP CELL THERAPY MANUFACTURING FACILITIES



DISEASE AREAS

Blood cancers
Breast (TNBC)
Lung (NSCLC)
Gastric
Gastroesophageal
Colorectal (CRC)
Melanoma
Head and Neck
Hepatocellular
Pancreatic
Glioblastoma (GBM)
Bile Duct Cancer



azer-cel Ph1b DLBCL (FDA IND)


nextHERIZON: Ph2 HER2+ Metastatic GC (FDA IND)

MAST: Ph1 Solid Tumors (FDA IND)

onCARlytics: Ph1 Solid Tumors (FDA IND)

PD1-Vaxx: Ph1 MSI-H CRC

LONG-LIFE PATENT PORTFOLIO



5

CLINICAL STUDIES

KEY CATALYSTS FOR THE NEXT 12 MONTHS

Q4 2023

- **AZER-CEL**: FPI on Ph1b
- **PD1-VAXX**: MSI-H activation

Q1 2024

- **ONCARLYTICS**: IT & IV Combination FPI
- **PD1-VAXX**: FPI Phase 2 MSI-H CRC

Q2 2024

- **AZER-CEL**: Phase 1b Enrollment Status
- **ONCARLYTICS**: FPI IT Combo Cohort 2
- **VAXINIA**: IT Mono Expansion Open

Q3 2024

- **AZER-CEL**: Phase 1b enrollment completed
- **ONCARLYTICS**: IV Combination Cohort 2 Open
- **VAXINIA**: IT Combination Expansion Cohort Open

Q4 2024

- **AZER-CEL**: Regulatory meeting with FDA
- **ONCARLYTICS**: IT & IV Combo Expansion
- **AZER-CEL**: DLBCL Phase 2 Pivotal Study Start-up
- **ONCARLYTICS** + **AZER-CEL** in solid tumours

Key: **FPI**, First Patient In, **MSI-H**: IV Microsatellite Instability High,

IV: Intravenous, **IT**: Intratumoural, **Mono**: Monotherapy, **DLBCL**: Diffuse Large B-Cell Lymphoma,

COMMERCIALISATION STRATEGY

Clinical Success Drives Value Realisation Opportunities

- Model for biotech commercialisation strategy is to out-license the technology to Big Pharma
- Out-licensing is highly dependent upon demonstrating safety in Phase 1 and convincing signals of efficacy in Phase 1b/2
- Licensing deals are generally structured with an up-front cash payment, payments upon reaching certain development milestones such as entering Phase 3 trials, payment on FDA approval of the drug, and royalties on net sales when the drug is on the market

COMPANY ACQUISITION

PARTNER WITH BIG PHARMA

LICENSE TECHNOLOGIES SEPARATELY

**DEVELOP /
COMMERCIALISE INDEPENDENTLY**

CELL THERAPY AND ONCOLYTIC VIRUS PLATFORMS DELIVER INNOVATIVE AND POTENT THERAPIES TO PATIENTS

**Allogeneic
CAR T
Cell Therapy**

azero-cel

**OnCARlytics
CF33-CD19
OV Therapy**

onCARlytics

**CF33
Oncolytic Virus
(OV) Therapy**

VAXINIA

**B Cell
Immunotherapy**


**HER-Vaxx
& PD1-Vaxx**

IMUGENE IS AN INDUSTRY LEADER IN ALLOGENEIC CELL THERAPY

- Imugene acquired azercabtagene zapreleucel (azer-cel) in August 2023
- Phase 1 trial was completed in 84 blood cancer patients with encouraging safety and efficacy data
- Patients with Diffuse Large B Cell Lymphoma (DLBCL) who relapsed after autologous (auto) CAR T therapy demonstrated an 83% overall response rate with 61% Complete Response Rate and 55% duration of response was ≥ 6 months
- Positive feedback from the FDA on Phase 1 results
- Phase 1b confirmatory study to enroll 10 DLBCL patients relapsed after auto-CAR T: **First Patient In on 10 November 2023**
- Strategy is to commence a Phase 2 registration study in the next 12-18 months

Mechanism of Action

CD19 is a common molecule found on blood cancers, so a CAR T therapy designed to attack CD19 is like a deadly missile against a cancer cell with CD19 on its surface



PHASE 2 POTENTIAL REGISTRATION TRIAL

Potential registrational study (subject to FDA approval) to start upon completion of the Phase 1b study H2 2024

Population: Diffuse large B cell lymphoma (DLBCL) patients who have relapsed after auto CAR T therapy

Positive initial FDA guidance on the potential registrational study received in July 2023

~35+ sites in the US: Phase 1b trial currently conducted at Moffit, COH, Karmanos, U Minnesota, Rhode Island, Cornell, Columbia

Drug product for Phase 1b trial completed

Drug is manufactured Imugene's facility in North Carolina



DukeHealth



City of
Hope®

THE OHIO STATE
UNIVERSITY

MOFFITT
CANCER CENTER



Masonic Cancer Center

UNIVERSITY OF MINNESOTA

PHASE 1 CF33 MAST STUDY

Making a Meaningful Impact for Patients



- The Phase 1 study treats advanced cancer patients intravenously (IV) or intratumorally (IT) with CF33-hNIS (VAXINIA) alone, or in combination with pembrolizumab in multiple solid cancers
- 34 heavily pre-treated patients dosed to date; doses have been determined to be safe and tolerable; 25 patients currently evaluable for response (received at least their first scan at 6 weeks)
- One Complete Response (iCR)* in bile duct cancer and one Partial Response (PR)* in melanoma at the mid level dose, 16 patients with Stable Disease (SD)
- 7 patients with gastrointestinal cancers who received CF33 alone including 3 colorectal cancer, 2 bile duct, 1 pancreatic and 1 liver cancer showed disease control (CR, PR and SD) of 86%
- Study expansion is planned for 10 additional patients with bile duct cancer
- Phase 1 trial is conducted at 12 centers in the US and Australia




*iRECIST and RECIST: (immune) Response evaluation criteria in solid tumours

*PFU: Plaque Forming Unit

FIRST PATIENT TREATED WITH ONCARLYTICS IN PHASE 1 OASIS STUDY OF METASTATIC ADVANCED SOLID TUMOURS

Combination treatment for solid tumours



- The Phase 1 study is designed to treat with onCARlytics (CF33-CD19) alone, or in combination with Blincyto® (bispecific antibody targeting CD19) and either dosed intravenously (IV) or intratumourally (IT) in metastatic advanced patients across multiple solid tumours

First patient enrolled (ovarian cancer) at City of Hope in October 2023


- Phase 1 planned for ~10 sites in the U.S.

- Many CD19 approved drugs which could become preferred partners to combine with onCARlytics (~90% of cancer)

ONCARLYTICS + AZER-CEL ERADICATES MULTIPLE TUMOUR TYPES IN EARLY PRECLINICAL STUDIES

- Azer-cel in combination with onCARlytics demonstrated sustained, robust activity against multiple tumour types
- 100% impressive killing of Triple Negative Breast Cancer and Gastric Cancer lines was observed compared to controls

Combination treatment for solid tumours



shareholderenquiries@imugene.com

www.imugene.com

ersonal use only

